Old Web
English
Sign In
Acemap
>
authorDetail
>
Julie Ann Rosenberg
Julie Ann Rosenberg
Pfizer
Follicular lymphoma
Biosimilar
Rituximab
CD20
Medicine
2
Papers
16
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
2019
BioDrugs
Jeff P. Sharman
Anna Marina Liberati
Kenichi Ishizawa
Tahira Khan
Jeffery Robbins
Ann Alcasid
Julie Ann Rosenberg
Igor Aurer
Show All
Source
Cite
Save
Citations (12)
A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)
2018
Blood
Jeff P. Sharman
Anna Marina Liberati
Rodrigo Santucci Silva
Igor Aurer
Jeffery Robbins
Julie Ann Rosenberg
Tahira Khan
Ann Alcasid
Show All
Source
Cite
Save
Citations (4)
1